-
公开(公告)号：WO2016189876A1
公开(公告)日：2016-12-01
申请号：PCT/JP2016/002557
申请日：2016-05-26
IPC分类号： C07D487/04 , C07D263/26 , C07D207/273 , C07D498/04 , C07D211/76 , C07D307/22 , A61K31/4985 , A61P35/00 , A61P37/00 , A61P11/00 , A61P25/28
CPC分类号： C07D211/76 , C07D207/273 , C07D263/26 , C07D307/22 , C07D487/04 , C07D498/04
摘要： The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
摘要翻译： 本发明提供具有甲酰基肽受体1（以下简称为FPRL1）激动剂效果的尿素衍生物或其药理学上可接受的盐，含有该脲衍生物或其药理学可接受的盐的药物组合物和药物用途 它们。 已经发现，下述通式（I）表示的尿素衍生物或其药理学上可接受的盐具有优异的FPRL1激动剂效果。 化合物（I）或其药理学上可接受的盐对于治疗，预防或抑制炎性疾病，慢性气道疾病，癌症，败血病，过敏症状，HIV逆转录病毒感染，循环障碍，神经炎症，神经障碍，疼痛，朊病毒 疾病，淀粉样变性，免疫障碍等。
-
公开(公告)号：WO2016189877A1
公开(公告)日：2016-12-01
申请号：PCT/JP2016/002559
申请日：2016-05-26
发明人： TAKAHASHI, Hiroyasu , WATANABE, Hiroyuki , FUJII, Kiyoshi , SHIBASAKI, Mitsuhito , KAWASHIMA, Mikako , KAMIYA, Megumi , OHATA, Kohei
IPC分类号： C07C275/50 , C07D311/58 , C07D231/12 , C07D333/16 , C07D333/28 , C07D239/36 , C07D413/04 , C07D413/12 , C07D417/12 , C07D249/04 , C07D249/08 , C07D249/12 , C07D257/04 , C07D261/08 , C07D263/32 , C07D263/34 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/113 , C07D273/04 , C07D277/28 , C07D285/08 , C07D285/12 , C07D285/135 , C07D213/61 , C07D307/79 , A61K31/415 , A61K31/4192 , A61K31/421 , A61K31/4245 , A61K31/433 , A61K31/44 , A61K31/381 , A61K31/353 , A61K31/343 , A61K31/5395 , A61K31/5377 , A61K31/41 , A61K31/454 , A61K31/42 , A61K31/513 , A61K31/427 , A61K31/428 , A61P29/00 , A61P35/00 , A61P37/00 , A61P31/18 , A61P25/00
CPC分类号： C07D257/04 , C07C275/30 , C07C275/42 , C07C275/50 , C07C311/51 , C07C317/32 , C07C317/40 , C07C2601/02 , C07D213/61 , C07D231/12 , C07D239/36 , C07D249/04 , C07D249/08 , C07D249/12 , C07D261/08 , C07D263/32 , C07D263/34 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/113 , C07D273/04 , C07D277/28 , C07D285/08 , C07D285/12 , C07D285/135 , C07D307/79 , C07D311/58 , C07D333/16 , C07D333/28 , C07D413/04 , C07D413/12 , C07D417/12
摘要： The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
摘要翻译： 本发明提供具有甲酰基肽受体1（以下简称为FPRL1）激动剂效果的尿素化合物或其药理学上可接受的盐，含有脲化合物或其药理学可接受的盐的药物组合物和药物用途 它们。 已经发现，由下述通式（I）表示的尿素衍生物或其药理学上可接受的盐具有优异的FPRL1激动剂效果。 化合物（I）或其药理学上可接受的盐对于治疗，预防或抑制炎性疾病，慢性气道疾病，癌症，败血病，过敏症状，HIV逆转录病毒感染，循环障碍，神经炎症，神经障碍，疼痛，朊病毒 疾病，淀粉样变性，免疫障碍等。
-
搜索结果
2 条记录 (耗时 0.013 秒)
